CoCites: A citation-based method for searching scientific literature

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management.

A Al-Janabi, Z Z N Yiu. Psoriasis (Auckl) 2022
Times Cited: 2

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.

Kristian Reich, Melinda Gooderham, Diamant Thaçi, Jeffrey J Crowley, Caitriona Ryan, James G Krueger, Tsen-Fang Tsai, Mary Flack, Yihua Gu, David A Williams, Elizabeth H Z Thompson, Carle Paul. Lancet 2019
Times Cited: 127

List of shared articles

Times cited

Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases.
Ana Ion, Alexandra Maria Dorobanțu, Liliana Gabriela Popa, Mara Mădălina Mihai, Olguța Anca Orzan. Biology (Basel) 2022